The IFFANIAM study (Impact of frailty and functional status in elderly patients with ST segment elevation myocardial infarction undergoing primary angioplasty) is an observational multicenter registry to assess the impact of frailty and functional status on outcomes of elderly patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary angioplasty. STEMI patients age 75 years or older undergoing primary angioplasty will be extensively studied during admission in 4 tertiary care Hospitals in Spain, assessing their baseline functional status (Barthel index, Lawton-Brody index), frailty (Fried criteria, FRAIL scale [fatigue, resistance, ambulation, illnesses, and loss of weight]), comorbidities (Charlson index), nutritional status (Mini Nutritional Assessment-Short Form), and quality of life (Seattle Angina Questionnaire). Participants will be managed according current recommendations. The primary outcome will be the description of 1-year mortality, its causes, and associated factors. Secondary outcomes will be functional capacity and quality of life. Results will help to better understand the impact of frailty and functional ability on outcomes in elderly STEMI patients undergoing primary angioplasty, thus potentially contributing to improving their clinical management. Higher life expectancy has resulted in a large segment of elderly population and an increase in myocardial infarction in these patients. This calls attention to healthcare systems to focus on promoting methods to improve the clinical management of this population. IntroductionCardiovascular disease is a major cause of morbidity and mortality in elderly patients. The incidence of myocardial infarction (MI) increases with age and is particularly high in the elderly. 1 In addition, comorbidities and frailty are common in this clinical setting and are associated with higher rates of complications, longer hospital stay, and consumption of healthcare resources. 2 Therefore, care of ST-segment elevation myocardial infarction (STEMI) in the elderly could become a public health problem in the coming years.Despite their relative importance within the spectrum of STEMI patients, elderly patients are usually poorly represented in clinical trials. 3,4 The clinical evidence on

No abstract

No abstract

No abstract